Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono adds Japan to Aurora kinase collaboration

Merck Serono exercises its option to add the Japanese territory to its current Aurora kinase collaboration which includes the lead product, R763/AS703569

Merck Serono, a division of German-based Merck KGaA, has exercised its option to add the Japanese territory to its current Aurora kinase collaboration which includes the lead product, R763/AS703569.

In exchange for these extended development and marketing rights, co-development partner US-based pharmaceutical company Rigel will receive a USD 3m payment.

In October 2005, the two companies entered into a worldwide collaboration, excluding Japan, to develop R763/AS703569 and other Aurora kinase inhibitors. As part of this agreement, Merck Serono had the right to add Japan to its territory.

R763/AS703569 is an oral, highly potent inhibitor of Aurora kinases and has exhibited anti-tumour activity against a broad range of cancer cell lines. To date, three phase I clinical trials with R763/AS703569, sponsored by Merck Serono, have been initiated and are ongoing in patients with solid tumors and leukemia.

If proven safe and efficacious, this regimen could dramatically alter the lives of patients with a variety of cancers including pancreatic, ovarian, breast, non-small cell lung and colorectal, as well as those with hematological malignancies.

Rigel's CEO Raul Rodriguez said: "Developing a novel, effective, oral therapeutic for cancer patients is the primary goal of our Aurora kinase collaboration with Merck Serono. We are proud that Merck Serono has re-affirmed its commitment to this programme."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...

Infographics